Marcelo Antonio Pinheiro Braga

Marcelo Antonio Pinheiro Braga

Auto-generated profile, based on publicly available information

Marcelo Antonio Pinheiro Braga

Postgraduate Program in Cardiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
ARAndré Rivera
André Rivera
DGDouglas Mesadri Gewehr
Douglas Mesadri Gewehr
MBMarcelo A. P. Braga
Marcelo A. P. Braga
PCPedro E. P. Carvalho
Pedro E. P. Carvalho
CTCaique M. P. Ternes
Caique M. P. Ternes
ADAndre D’Avila
Andre D’Avila

11 November 2023 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
TCThomaz Alexandre Costa
Thomaz Alexandre Costa
NFNicole Felix
Nicole Felix
MCMariana Clemente
Mariana Clemente
LTLarissa Teixeira
Larissa Teixeira
MBMarcelo Antonio Pinheiro Braga
Marcelo Antonio Pinheiro Braga
LSLivia Teixeira Martins Silva
Livia Teixeira Martins Silva

22 July 2025 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
MBMarcelo A. P. Braga
Marcelo A. P. Braga
ARAndré Rivera
André Rivera
GMGabriel Marinheiro
Gabriel Marinheiro
NFNicole Felix
Nicole Felix
PCPedro E. P. Carvalho
Pedro E. P. Carvalho
RRRanjith Ramasamy
Ranjith Ramasamy

1 July 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
DGDouglas Mesadri Gewehr
Douglas Mesadri Gewehr
PCPedro E P Carvalho
Pedro E P Carvalho
FMFelipe Villa Martignoni
Felipe Villa Martignoni
ANAlleh Nogueira
Alleh Nogueira
CGCintia Gomes
Cintia Gomes
EJEmilton Lima Junior
Emilton Lima Junior
Aims: The comparative effectiveness of specific antihypertensive agents in preventing new-onset or recurrent atrial fibrillation (AF) remains under debate. This study aimed to evaluate the impact of different antihypertensive agents on AF risk. Methods and results: Medline, Cochrane, EMBASE, and ClinicalTrials.gov databases were searched for randomized controlled trials (RCTs) reporting AF events as a predefined outcome. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), dihydropyridine calcium channel blockers (CCBs), β-blockers, mineralocorticoid antagonists (MRAs), and thiazide diuretics (TDs) were analyzed. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a Bayesian random-effects network meta-analysis (NMA). Treatments were ranked using the surface under the cumulative ranking (SUCRA). Twenty-two RCTs randomising 66,156 patients with hypertension, diabetes, or AF were included. ACE inhibitors plus TD (RR 0.44; 95% CrI 0.23–0.82), ACE inhibitors (RR 0.66; 95% CrI 0.44–0.95), and ARBs (RR 0.52; 95% CrI 0.38–0.70) were associated with lower rates of new-onset or recurrent AF compared with CCBs. SUCRA ranked ACE inhibitors plus TD (0.86) as the best, followed by ARBs (0.77), MRAs (0.75), and ACE inhibitors (0.53) for preventing AF events. These findings were consistent across secondary and sensitivity analyses. Conclusion: In this NMA comparing multiple antihypertensive regimens in patients with hypertension, diabetes, or AF, ACE inhibitors plus TD, ACE inhibitors, and ARBs were the most effective in reducing AF events, outperforming CCBs. Registration: PROSPERO Database (CRD42024588765).

4 December 2024 in World Journal of Surgery
Verified
Journal Article
Closed access
EPEric Pasqualotto
Eric Pasqualotto
BPBernardo Fontel Pompeu
Bernardo Fontel Pompeu
MBMarcelo A. P. Braga
Marcelo A. P. Braga
LDLucas Monteiro Delgado
Lucas Monteiro Delgado
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
FFFernanda Bellotti Formiga
Fernanda Bellotti Formiga

18 March 2026 in Heart Rhythm O2
Verified
Journal Article
Open access
MBMarcelo A.P. Braga
Marcelo A.P. Braga
CTCaique M.P. Ternes
Caique M.P. Ternes
ARAndré Rivera
André Rivera
IFIuri Ferreira Felix
Iuri Ferreira Felix
CDChristopher V. DeSimone
Christopher V. DeSimone
ADAndre D’Avila
Andre D’Avila
Sex differences in atrial fibrillation (AF) treatment remain unexplored in low- and middle-income settings. Women are less often referred for catheter ablation for AF, and whether procedural efficacy and safety differ by sex remains unclear in this population. The purpose of this study was to evaluate sex-based differences in baseline characteristics and clinical outcomes among patients with AF who underwent first-time radiofrequency catheter ablation in the Southern Brazilian Registry of Atrial Fibrillation (SBR-AF), a Latin American multicenter prospective registry with ≥12 months of follow-up. The primary end point was any atrial tachyarrhythmia recurrence. Safety outcomes included periprocedural complications through hospital discharge. In our cohort of 1130 patients, 315 (27.9%) were women. Women were older, were more symptomatic, and had higher thromboembolic risk scores at the time of ablation. Paroxysmal AF was more common in women (82.2% vs 72.3%), whereas persistent AF predominated among men. Over a median follow-up of 1.4 years (interquartile range 1.0–3.6 years), atrial tachyarrhythmia recurrence occurred in 23.5% of women and 19.5% of men (log-rank, P = .14). In paroxysmal AF, men demonstrated greater freedom from recurrence (hazard ratio 0.74; 95% confidence interval 0.51–0.99), whereas outcomes were similar in persistent AF. In men, persistent AF and greater symptom burden independently predicted recurrence; no independent predictors emerged among women. The overall complication rate was 4.2%, with similar safety profiles between sexes. In the largest, real-world, multicenter, prospective cohort of AF ablation in Latin America, women underwent ablation at older ages with greater symptom burden yet achieved efficacy and safety comparable to men.